Literature DB >> 6404817

Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide.

S J Cryz, E Fürer, R Germanier.   

Abstract

The protective capacity of passively transferred immunoglobulin G (IgG) fractions from antitoxin (AT-IgG), antielastase (AE-IgG), and antilipopolysaccharide (ALPS-IgG) against Pseudomonas aeruginosa infection was evaluated in a murine burn wound sepsis model. Complete protection was afforded by homologous ALPS-IgG against intermediate challenge doses (10 50% lethal doses) of P. aeruginosa PA220, whereas AT-IgG and AE-IgG offered no significant protection (P less than 0.5). The simultaneous transfer of AT-IgG or AE-IgG with ALPS-IgG gave no additional protection above that seen with ALPS-IgG alone. The transfer of ALPS-IgG did not dramatically alter bacterial multiplication in the skin at the site of infection. However, bacteremia and infection of the liver were prevented. In parallel experiments, AT-IgG or AE-IgG did not significantly alter either the course of the infection or the number of bacteria seen in the blood, liver, or skin when compared with controls. ALPS-IgG administered 24 h before infection, at the time of infection, or 4 h postinfection provided complete protection. Even when ALPS-IgG was transferred at a time when the infection was well established locally in the skin (8 h postinfection), highly significant protection (P greater than 0.999) was obtained. Protection afforded by ALPS-IgG was serotype specific. These results indicate that antibody to lipopolysaccharide is of critical importance for protection against P. aeruginosa challenge in a relevant animal model.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404817      PMCID: PMC348065          DOI: 10.1128/iai.39.3.1072-1079.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  39 in total

1.  NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,.

Authors:  B H Iglewski; D Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

Review 2.  Burn wounds: microbiology, local host defenses, and current therapy.

Authors:  P Nathan; I A Holder; B G MacMillan
Journal:  CRC Crit Rev Clin Lab Sci       Date:  1973-07

3.  Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia.

Authors:  M Haghbin; D Armstrong; M L Murphy
Journal:  Cancer       Date:  1973-10       Impact factor: 6.860

4.  Corneal ulcers caused by protease and elastase from Pseudomonas aeruginosa.

Authors:  K Kawaharajo; C Abe; J Y Homma; M Kawano; E Goto
Journal:  Jpn J Exp Med       Date:  1974-10

5.  Type-specific immunity in pseudomonas diseases.

Authors:  J G Crowder; M W Fisher; A White
Journal:  J Lab Clin Med       Date:  1972-01

6.  Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.

Authors:  L S Young
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

7.  Large-scale purification and characterization of the exotoxin of Pseudomonas aeruginosa.

Authors:  S H Leppla
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

8.  Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection.

Authors:  M Pollack; L T Callahan; N S Taylor
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

9.  Effects of protease and elastase from Pseudomonas aeruginosa on skin.

Authors:  K Kawaharajo; J Y Homma; Y Aoyama; K Okada; K Morihara
Journal:  Jpn J Exp Med       Date:  1975-04

10.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model.

Authors:  D D Stieritz; I A Holder
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

View more
  39 in total

1.  Pseudomonas aeruginosa cell-to-cell signaling is required for virulence in a model of acute pulmonary infection.

Authors:  J P Pearson; M Feldman; B H Iglewski; A Prince
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice.

Authors:  I A Holder; A N Neely; D W Frank
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

3.  Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia.

Authors:  J E Pennington; G J Small; M E Lostrom; G B Pier
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

4.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

5.  Immunochemical and biochemical analysis of the polyvalent Pseudomonas aeruginosa vaccine PEV.

Authors:  S MacIntyre; T McVeigh; P Owen
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

6.  Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites.

Authors:  J U Que; S J Cryz; R Ballou; E Fürer; M Gross; J Young; G F Wasserman; L A Loomis; J C Sadoff
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

7.  Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice.

Authors:  T Matsumoto; K Tateda; S Miyazaki; N Furuya; A Ohno; Y Ishii; Y Hirakata; K Yamaguchi
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

8.  Preparation and characterization of a nontoxic polysaccharide-protein conjugate that induces active immunity and passively protective antibody against Pseudomonas aeruginosa immunotype 1 in mice.

Authors:  G C Tsay; M S Collins
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

9.  Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa.

Authors:  S J Cryz; T L Pitt; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

10.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.